Enveric Biosciences, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Selling, general & administrative | — | — | — | — | $20.5M |
| Research and development | $2.8M | $2.8M | $7.3M | $8.0M | $4.8M |
| Operating income | -$8.8M | -$9.6M | -$16.4M | -$27.4M | -$64.6M |
| Interest expense | — | — | — | $5,249 | $10,316 |
| Pretax income | -$8.8M | -$9.6M | -$17.3M | -$20.0M | -$56.4M |
| Income tax expense | — | $8,930 | $28,913 | -$1.5M | -$7.5M |
| Net income | -$8.8M | -$9.6M | -$17.3M | -$18.5M | -$49.0M |
| Balance Sheet | |||||
| Current assets | $4.9M | $2.7M | $3.6M | $18.4M | $17.7M |
| Total assets | $5.1M | $3.1M | $4.3M | $19.6M | $26.7M |
| Current liabilities | $918,400 | $1.5M | $2.3M | $4.0M | $2.7M |
| Total liabilities | — | — | — | $4.0M | $4.4M |
| Stockholders' equity | $4.2M | $1.6M | $2.0M | $14.7M | $22.3M |
| Cash Flow Statement | |||||
| Cash from operations | -$8.1M | -$7.7M | -$14.1M | -$17.1M | -$11.5M |
| Depreciation and amortization | $158,676 | $168,739 | $175,228 | $159,160 | $13,310 |
| Stock-based compensation | $827,323 | $1.6M | $2.2M | $2.6M | $12.6M |
| Capital expenditure | — | — | $5,180 | $584,165 | $189,719 |
| Free cash flow | — | — | -$14.1M | -$17.7M | -$11.6M |
| Impairments | — | — | — | $6.0M | $29.0M |
Shares outstanding 3.7M · Free float 98.8%
Annual filing data through FY ended December 31, 2025; float as of July 11, 2026.